BriaCell reports sustained complete resolution of lung metastasis in Bria-OTS

BriaCell (BCTX) Therapeutics announces the durable and sustained complete resolution of a lung metastasis in a patient with metastatic breast cancer treated with Bria-OTS, BriaCell’s personalized off the shelf immunotherapy. The patient is hormone receptor-positive, HER2-negative. The first patient enrolled in the Bria-OTS study, a 78-year-old woman with advanced metastatic breast cancer and multiple prior treatment failures, achieved complete resolution of a lung metastasis following four doses of Bria-OTS single agent therapy. The complete response, initially observed at 2 months, was subsequently confirmed at 4 months, 6 months, and now at 11 months. The patient received 17 cycles of Bria-OTS, completed 12 months of the study, and remains in survival follow-up.